JPC News Alert Nuveen Preferred and Convertible (JPC) 9.28 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 5:49 PM

Nuveen Preferred and Convertible (JPC) 9.28 $JPC

In Search Of Income: Preferred CEFs (Part II)
Convergence Investments - at Seeking Alpha - Sun Dec 14, 5:27PM CST

HPI: 20.64 (unch), FPF: 21.65 (-0.07), JPC: 9.28 (+0.01), DFP: 22.76 (-0.04), HPS: 18.14 (-0.14), JPI: 22.45 (-0.07), JTP: 8.10 (-0.15), JHP: 8.33 (-0.06), PDT: 13.80 (-0.10), PSF: 26.36 (-0.12), HPF: 20.52 (-0.11), LDP: 23.44 (-0.01), JPS: 8.95 (-0.09)

Thursday's Ex-Dividends To Watch: NPF, NKX, JPC
at The Street - Wed Dec 10, 9:04AM CST
NPF NKX JPC are going ex-dividend Thursday, Thursday, December 11, 2014
NPF: 13.96 (+0.01), NKX: 14.62 (-0.08), JPC: 9.28 (+0.01)

Nuveen Closed-End Funds to Host Series of Market Update Conference Calls
Business Wire - Tue Dec 09, 4:50PM CST
--First Call of 2015 will Highlight Global Debt Funds
JPC: 9.28 (+0.01)

Nuveen Closed-End Funds Declare Monthly Distributions
Business Wire - Mon Dec 01, 4:55PM CST
Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that 75 Nuveen closed-end funds declared regular monthly distributions. These funds represent a broad range of tax-exempt, taxable fixed and floating rate income investment strategies for investors seeking to build sophisticated and diversified long-term investment portfolios for cash flow. The funds' monthly distributions are listed below.
NTC: 12.51 (-0.05), NKG: 12.49 (-0.03), NBD: 21.65 (-0.04), NOM: 15.20 (+0.17), JLS: 23.02 (-0.01), JQC: 8.62 (-0.01), NXC: 15.36 (-0.05), JPI: 22.45 (-0.07), JTP: 8.10 (-0.15), JHP: 8.33 (-0.06), NKX: 14.62 (-0.08), NBB: 20.85 (unch), NSL: 6.46 (-0.05), JPS: 8.95 (-0.09), NAZ: 14.23 (-0.03), JPW: 16.38 (-0.01), NNC: 12.97 (+0.01), NVX: 14.32 (+0.09), JMT: 22.65 (+0.06), JMM: 7.83 (+0.01), NJV: 14.69 (-0.10), NCB: 16.75 (unch), NCA: 10.53 (-0.08), NNP: 14.48 (+0.07), NRK: 12.97 (+0.01), NNY: 9.81 (+0.10), NMI: 11.79 (+0.01), NVG: 14.11 (+0.03), NQI: 13.12 (unch), JSD: 16.70 (-0.10), NZF: 13.81 (+0.01), NQM: 15.27 (+0.05), NUW: 17.20 (-0.08), NMA: 13.61 (+0.02), NQP: 13.70 (-0.06), NZH: 13.36 (+0.06), NQS: 13.92 (+0.01), JRI: 19.06 (+0.08), JFR: 10.88 (+0.14), NMY: 12.60 (-0.02), NQU: 13.94 (+0.01), NUO: 15.25 (-0.02), NMZ: 13.41 (+0.03), JRO: 11.22 (+0.09), NUV: 9.60 (unch), NMO: 13.54 (-0.02), NYV: 14.57 (-0.04), NMS: 14.47 (+0.03), NMT: 13.13 (-0.03), NUM: 13.67 (-0.03), NEV: 15.01 (+0.01), NIQ: 12.65 (-0.03), NIO: 14.56 (+0.03), NIM: 10.81 (unch), NPI: 13.80 (+0.01), NPF: 13.96 (+0.01), DRA: 17.25 (unch), NPM: 14.02 (-0.02), JPC: 9.28 (+0.01), NTX: 14.49 (-0.05), NPP: 14.76 (-0.02), NPN: 15.10 (+0.05), NPT: 13.29 (+0.03), NXK: 13.14 (+0.05), NXN: 13.50 (-0.10), NAD: 14.27 (+0.02), NEA: 13.73 (+0.01), NAC: 14.92 (-0.01), NXP: 14.14 (+0.01), NPV: 13.18 (unch), NXQ: 13.52 (-0.02), NXR: 14.25 (-0.02), NAN: 13.43 (-0.06), NID: 12.54 (+0.05)

The Pure Income Portfolio Alternative: Closed End Income Funds
Bruce Miller - Seeking Alpha - Sat Nov 15, 12:09PM CST
Part I of The Pure Income Portfolio dealt with the 'core' income securities. The Subsequent article looked at 'Alternative' income securities of managed mutual funds and Exchange Traded Funds. Due to the length of each of these, I'll be writing...
DDF: 9.98 (+0.03), JPC: 9.28 (+0.01)

Ex-Dividends To Watch: 3 Stocks Going Ex-Dividend Tomorrow: JRS, CLM, JPC
at The Street - Wed Sep 10, 9:06AM CDT
JRS CLM JPC are going ex-dividend tomorrow, Thursday, September 11, 2014
JRS: 11.57 (unch), JPC: 9.28 (+0.01), CLM: 5.06 (-0.04)

Nuveen Announces Results of Closed-End Fund Shareholder Meetings
Business Wire - Tue Aug 19, 3:30PM CDT
--Investment Management & Sub-Advisory Agreements Approved
JDD: 11.96 (+0.04), NTC: 12.51 (-0.05), NKG: 12.49 (-0.03), NBD: 21.65 (-0.04), NOM: 15.20 (+0.17), JLS: 23.02 (-0.01), JQC: 8.62 (-0.01), NXC: 15.36 (-0.05), JPI: 22.45 (-0.07), JTP: 8.10 (-0.15), JHP: 8.33 (-0.06), JPG: 14.35 (+0.06), NBB: 20.85 (unch), NKX: 14.62 (-0.08), NSL: 6.46 (-0.05), JPS: 8.95 (-0.09), NAZ: 14.23 (-0.03), JPW: 16.38 (-0.01), NNC: 12.97 (+0.01), NVX: 14.32 (+0.09), JMT: 22.65 (+0.06), NNJ: 13.68 (+0.01), NJV: 14.69 (-0.10), NCB: 16.75 (unch), NNP: 14.48 (+0.07), NCA: 10.53 (-0.08), NRK: 12.97 (+0.01), JMF: 20.17 (-0.08), NNY: 9.81 (+0.10), NMI: 11.79 (+0.01), NVG: 14.11 (+0.03), NQI: 13.12 (unch), NQJ: 13.30 (+0.01), JSD: 16.70 (-0.10), NZF: 13.81 (+0.01), NUW: 17.20 (-0.08), NMA: 13.61 (+0.02), NQP: 13.70 (-0.06), NZH: 13.36 (+0.06), NQS: 13.92 (+0.01), JRI: 19.06 (+0.08), JFR: 10.88 (+0.14), NMY: 12.60 (-0.02), NQU: 13.94 (+0.01), NUO: 15.25 (-0.02), NMZ: 13.41 (+0.03), JRO: 11.22 (+0.09), NUV: 9.60 (unch), JRS: 11.57 (unch), NMO: 13.54 (-0.02), NUJ: 13.25 (-0.01), NYV: 14.57 (-0.04), NUM: 13.67 (-0.03), NEV: 15.01 (+0.01), NXZ: 14.10 (+0.03), NIQ: 12.65 (-0.03), JCE: 17.53 (+0.37), NIO: 14.56 (+0.03), NIM: 10.81 (unch), NPI: 13.80 (+0.01), NPF: 13.96 (+0.01), JTA: 13.49 (+0.04), NPM: 14.02 (-0.02), JPC: 9.28 (+0.01), NTX: 14.49 (-0.05), JTD: 16.10 (+0.07), NPP: 14.76 (-0.02), NPN: 15.10 (+0.05), NXJ: 13.43 (+0.01), NPT: 13.29 (+0.03), NXK: 13.14 (+0.05), JMLP: 15.53 (-0.02), NAD: 14.27 (+0.02), NXN: 13.50 (-0.10), NEA: 13.73 (+0.01), NAC: 14.92 (-0.01), NXP: 14.14 (+0.01), NPV: 13.18 (unch), NXQ: 13.52 (-0.02), NXR: 14.25 (-0.02), NAN: 13.43 (-0.06), JGV: 12.82 (+0.07), NID: 12.54 (+0.05)

Nuveen Preferred Income Opportunities Fund Announces Policy Change
Business Wire - Thu Aug 14, 5:02PM CDT
Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that the Board of Trustees of the Nuveen Preferred Income Opportunities Fund (NYSE: JPC) has approved a change to the fund's investment policies.
JPC: 9.28 (+0.01)

Tomorrow's Ex-Dividends To Watch: MQT, MYD, JPC
at The Street - Tue Aug 12, 9:05AM CDT
MQT MYD JPC are going ex-dividend tomorrow, Wednesday, August 13, 2014
MYD: 14.56 (+0.03), MQT: 13.19 (-0.08), JPC: 9.28 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

CVS Study: GLP-1 Drugs Effective But Costly

By Hannah Lewis Updated Nov 15, 2026 Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....